Fulgent Genetics (NASDAQ:FLGT – Get Rating) released its quarterly earnings data on Thursday. The company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05, Briefing.com reports. The firm had revenue of $125.30 million during the quarter, compared to analyst estimates of $122.70 million. Fulgent Genetics had a return on equity of 41.13% and a net margin of 48.32%. The business’s quarterly revenue was down 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.47 earnings per share. Fulgent Genetics updated its Q3 2022 guidance to EPS and its FY 2022 guidance to $6.00-$6.00 EPS.
Fulgent Genetics Stock Down 6.1 %
Fulgent Genetics stock traded down $3.88 during midday trading on Friday, reaching $59.86. 417,490 shares of the stock traded hands, compared to its average volume of 401,285. The stock’s fifty day moving average is $55.73 and its 200-day moving average is $58.34. Fulgent Genetics has a 12 month low of $47.34 and a 12 month high of $112.00. The stock has a market cap of $1.82 billion, a P/E ratio of 4.05 and a beta of 1.47.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on FLGT shares. TheStreet lowered Fulgent Genetics from a “b-” rating to a “c+” rating in a research note on Thursday, July 28th. Piper Sandler dropped their price objective on Fulgent Genetics from $85.00 to $70.00 in a research note on Sunday, May 15th.
Insider Activity at Fulgent Genetics
Institutional Investors Weigh In On Fulgent Genetics
Institutional investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Fulgent Genetics by 25.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 24,905 shares of the company’s stock valued at $1,554,000 after purchasing an additional 5,106 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Fulgent Genetics in the 1st quarter valued at approximately $1,264,000. Citigroup Inc. lifted its stake in shares of Fulgent Genetics by 3.6% in the 1st quarter. Citigroup Inc. now owns 20,152 shares of the company’s stock valued at $1,258,000 after purchasing an additional 702 shares during the last quarter. Sei Investments Co. bought a new stake in shares of Fulgent Genetics in the 1st quarter valued at approximately $1,243,000. Finally, Yousif Capital Management LLC lifted its stake in shares of Fulgent Genetics by 2.8% in the 1st quarter. Yousif Capital Management LLC now owns 19,805 shares of the company’s stock valued at $1,236,000 after purchasing an additional 540 shares during the last quarter. 37.61% of the stock is owned by institutional investors.
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.
- Get a free copy of the StockNews.com research report on Fulgent Genetics (FLGT)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.